Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19
| dc.contributor.author | Muskiet, Frits A. J. | |
| dc.contributor.author | Carrera Bastos, Pedro | |
| dc.contributor.author | Pruimboom, Leo | |
| dc.contributor.author | Lucía Mulas, Alejandro | |
| dc.contributor.author | Furman, David | |
| dc.date.accessioned | 2022-05-25T09:43:38Z | |
| dc.date.available | 2022-05-25T09:43:38Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Obesity, and obesity-associated conditions such as hypertension, chronic kidney disease, type 2 diabetes, and cardiovascular disease, are important risk factors for severe Coronavirus disease-2019 (COVID-19). The common denominator is metaflammation, a portmanteau of metabolism and inflammation, which is characterized by chronically elevated levels of leptin and pro-inflammatory cytokines. These induce the “Suppressor Of Cytokine Signaling 1 and 3” (SOCS1/3), which deactivates the leptin receptor and also other SOCS1/3 sensitive cytokine receptors in immune cells, impairing the type I and III interferon early responses. By also upregulating SOCS1/3, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 adds a significant boost to this. The ensuing consequence is a delayed but over-reactive immune response, characterized by high-grade inflammation (e.g., cytokine storm), endothelial damage, and hypercoagulation, thus leading to severe COVID-19. Superimposing an acute disturbance, such as a SARS-CoV-2 infection, on metaflammation severely tests resilience. In the long run, metaflammation causes the “typical western” conditions associated with metabolic syndrome. Severe COVID-19 and other serious infectious diseases can be added to the list of its short-term consequences. Therefore, preventive measures should include not only vaccination and the well-established actions intended to avoid infection, but also dietary and lifestyle interventions aimed at improving body composition and preventing or reversing metaflammation. | spa |
| dc.description.filiation | UEM | spa |
| dc.description.impact | 5.9 Q1 JCR 2022 | spa |
| dc.description.impact | 1.291 Q1 SJR 2022 | spa |
| dc.description.impact | No data IDR 2022 | spa |
| dc.description.sponsorship | Sin financiación | spa |
| dc.identifier.citation | Muskiet, F., Carrera-Bastos, P., Pruimboom, L., Lucía, A., & Furman, D. (2022). Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19. Nutrients, 14(7), 1388. https://doi.org/10.3390/nu14071388 | spa |
| dc.identifier.doi | 10.3390/nu14071388 | |
| dc.identifier.issn | 2072-6643 | |
| dc.identifier.uri | http://hdl.handle.net/11268/11296 | |
| dc.language.iso | eng | spa |
| dc.peerreviewed | Si | spa |
| dc.rights | Atribución 4.0 Internacional | * |
| dc.rights.accessRights | open access | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.other | COVID-19 | spa |
| dc.subject.unesco | Obesidad | spa |
| dc.subject.unesco | Efectos fisiológicos | spa |
| dc.subject.unesco | Virus | spa |
| dc.title | Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19 | spa |
| dc.type | journal article | spa |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | d3691359-d7bd-4a12-b84e-338e28c81f9f | |
| relation.isAuthorOfPublication.latestForDiscovery | d3691359-d7bd-4a12-b84e-338e28c81f9f |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Lucía_Nutrients_2022.pdf
- Size:
- 1.48 MB
- Format:
- Adobe Portable Document Format
- Description:
- Versión del editor

